And the SPACs just keep coming….
The ARYA Sciences team dropped their latest SPAC this morning by filing ARYA Sciences Acquisition Corp. II (ARYBU), a $125 million SPAC focused on the healthcare sector. Once again, ARYA II will be sponsored by Perceptive Advisors, one of the most well known life sciences hedge funds. Futhermore, ARYA II will be led by Joseph Edelman, as Chairman, and Adam Stone as CEO and Director, both having previously led the first ARYA.
This latest SPAC is a near carbon copy of the first SPAC, which has nearly the same team (with the exception of one Director), same size ($125 million), same focus (healthcare in North America or Europe and specifically, life sciences and med tech), and same lead banker (Jefferies). Additionally, ARYA II will employ an “Indication of Interest” forward purchase of up to $25 million by the sponsor. Exact same as in ARYA I. However, what about the differences…
Notably, ARYA II has added Goldman Sachs to the cover, albeit to the right of Jefferies. Additionally, the terms have gotten a little better for this go-around, but keep in mind that the first ARYA is currently looking to close its combination with Immatics and the share price is currently trading at $10.85, so this should be a successful deal. That kind of result commands better terms.
As for the terms specifically, ARYA II will be asking this time for a 1/3 warrant, rather than the 1/2 warrant they had previously. Additionally, ARYA II will be a 24 months, $10.00 in trust (100%) SPAC, with the ability now to call the warrants for shares at $10.00 (in additional to cash or cashless exercise at $18.00).
On the whole, the terms aren’t that different if you line them up side by side. The main difference is the 1/3 vs. 1/2 warrant. However, again, this team has the very important SPAC experience, which is successful SPAC experience at that. As such, the terms fit.
This deal should have no trouble selling. They’re a team with a hot-hand and they’ll be looking in a currently favorable sector, in which this team has experience in spades. They could probably easily upsize, but if we look to their first SPAC for guidance, ARYA I did not upsize despite huge demand, so perhaps they’ll be following the same playbook. Look for ARYA II to price early June.
Summary of terms below:
With a few days passed for the dust to settle on the re-election of President Donald Trump, the market still appears to be sorting out what to expect from the future administration. While SPACs are of course impacted by all general market shifts, there are some key changes that could impact SPACs and their transactions...
A SPAC III Acquisition Corp. (NASDAQ:ASPCU) announced the pricing of its $55 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ASPCU”, Friday, November 8, 2024. The new SPAC intends to seek out a target company with strong ESG principals in the material technology sector with potential for...
At the SPAC of Dawn Despite all of the worries and volatility, election week comes to an end today with de-SPACs up nearly across the board. Companies that closed SPAC transactions since 2021 are up a median +6% since their close on the eve of Tuesday’s elections and the cohort trading above $10 have seen...
Willow Lane Acquisition Corp. (NASDAQ:WLACU) announced the pricing of its $110 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “WLACU”, Friday, November 8, 2024. The new SPAC intends to conduct a broad search to find an established middle market company valued at about $1 billion or less....
GSR III Acquisition Corp. (NASDAQ:GSRTU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GSRTU”, Thursday, November 7, 2024. The new SPAC intends to mount a broad search for a target company without limitations on a particular industry, sector or geographic region....